Search results for "ABO"

showing 10 items of 13628 documents

Ein Beitrag zur Erkl�rung der Erregbarkeitssteigerung des Herzens bei Thyreotoxikose

1963

Investigations of thyroid hormone actions upon electrolyte exchange in body and tissues and upon electrophysiological properties of the heart, described in literature, are reviewed. Possible interactions of thyroid hormone effects upon efficiency of oxydative phosphorylation, upon electrolyte exchange and upon the excitability of the heart are discussed.

medicine.medical_specialtyChemistryThyroidEnergy metabolismGeneral MedicineOxidative phosphorylationMolecular medicineEndocrinologymedicine.anatomical_structureInternal medicineThyroid hormonesDrug DiscoverymedicineMolecular MedicineWater-Electrolyte BalanceGenetics (clinical)HormoneKlinische Wochenschrift
researchProduct

Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency

2003

Summary objective Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. design A multicentre, randomized, double-blind, and placebo-controlled study. patients Ninety-seven GHD adults were included. measurements The GH response before and after 1 week of oral treatment with NN703 (n = 83) or placebo (n = 14) was determined. The first and last dose of NN703 was 3 mg/kg, whereas the dose of NN703 was 1·5 mg/kg/day during the 6 days between the first and last doses. Furthermore, all 97 patients received 1 µg/kg GH-releasing hormone (GHRH) 3 weeks afte…

medicine.medical_specialtyChemotherapybusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPlacebomedicine.diseaseGrowth hormone deficiencyEndocrinologyBlood pressureEndocrinologyOral administrationGrowth hormone secretagogueInternal medicineStatistical significancemedicinebusinessHormoneClinical Endocrinology
researchProduct

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults

1988

Abstract Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic o…

medicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAntimetaboliteGastroenterologySurgeryRegimenRefractoryAcute lymphocytic leukemiaInternal medicineToxicitymedicineCytarabinebusinessAmsacrinemedicine.drugBlood
researchProduct

Glucose Metabolism in Children With Growth Hormone Deficiency

2018

Background: The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis has a fundamental impact on glucose metabolism. Therefore, both untreated GH deficiency (GHD) and GH treatment (GHT) may be associated with some metabolic alterations, although the abnormalities of glucose metabolism have been investigated by relatively few studies as main outcomes. Aim: The present review summarizes the available data on glucose metabolism in children with GHD, providing an overview of the current state of the art in order better to clarify the real metabolic impact of GHD and GHT. Methods: Among all the existing studies, we evaluated all original studies that fulfilled our criteria for analysis …

medicine.medical_specialtyChildren; Glucose; Growth hormone; Insulin sensitivity; Metabolism; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismMini Review030209 endocrinology & metabolismCarbohydrate metabolismGrowth hormonelcsh:Diseases of the endocrine glands. Clinical endocrinologyReporting parametersGrowth hormone deficiencySettore MED/13 - EndocrinologiaFasting glucose03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologychildrenInternal medicinemedicineGlucose homeostasisinsulin sensitivityglucoselcsh:RC648-665business.industryMetabolismmedicine.diseaseEndocrinology030220 oncology & carcinogenesisgrowth hormonebusinessmetabolismFrontiers in Endocrinology
researchProduct

Chloride/sodium ratio and sodium.chloride difference inpatients with renal failure and metabolic acidosis in hemodialysis treatment

2018

medicine.medical_specialtyChloride sodiumbusiness.industrySodiummedicine.medical_treatmentClinical Biochemistrychemistry.chemical_elementMetabolic acidosismedicine.diseaseBiochemistryInorganic ChemistryEndocrinologychemistryInternal medicinemedicinemetabolic acidosis chloirde/sodium ratio sodium-chloride difference Stewart's methodIn patientHemodialysisbusiness
researchProduct

Hyperlipidemia Prevalence and Cholesterol Control in OSA: Data from European Sleep Apnea Database (ESADA)

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyCholesterolbusiness.industryConfoundingnutritional and metabolic diseasesSleep apneaDiseasemedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneachemistry.chemical_compoundstomatognathic systemchemistryInternal medicineCohortHyperlipidemiamedicineIn patientbusinessHypoxia
researchProduct

Familial Combined Hyperlipidemia, Metabolic Syndrome and Cardiovascular Disease

2006

Our aim was to investigate the relationship between metabolic syndrome and cardiovascular disease (i.e., survivors of myocardial infarction) in patients with familial combined hyperlipidemia (FCH). We compared a group of 20 male patients with FCH who had survived a myocardial infarction with two other groups matched for age and body mass index, comprising 20 individuals with FCH who had not had a myocardial infraction and 20 control subjects. Plasma lipid, glucose, and insulin levels were determined. Metabolic syndrome was judged to present on the basis of World Health Organization (WHO) and National Cholesterol Education Program-Adult treatment panel (NCEP-ATPIII) criteria. Differences bet…

medicine.medical_specialtyCholesterolbusiness.industryInsulinmedicine.medical_treatmentGeneral MedicineDiseasemedicine.diseaseLogistic regressionchemistry.chemical_compoundInsulin resistancechemistryInternal medicinemedicineCardiologyMyocardial infarctionMetabolic syndromebusinessBody mass indexRevista Española de Cardiología (English Edition)
researchProduct

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

2020

The rising prevalence of the metabolic syndrome has led to an increase of non-alcoholic fatty liver disease (NAFLD), and its progressive-inflammatory form called non-alcoholic steatohepatitis (NASH). In recent years, NAFLD and NASH have become major risk factors for developing liver cirrhosis and hepatocellular carcinoma (HCC). In this case, we report a 46-year-old patient with type 2 diabetes mellitus and metabolic comorbidities including obesity and arterial hypertension, who was referred because of rising liver enzymes. After clinical and diagnostic evaluation, the patient was diagnosed with NASH-associated liver cirrhosis, Child-Pugh stage B. A normal blood sugar level was difficult to …

medicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityLiver transplantationChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineFatal OutcomeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineObesityMetabolic Syndromebusiness.industryFatty liverLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesDiabetes Mellitus Type 2Hepatocellular carcinomaHypertension030211 gastroenterology & hepatologyMetabolic syndromeSteatohepatitisInsulin ResistancebusinessZeitschrift fur Gastroenterologie
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association wi…

2016

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyCirrhosisDisease030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseMedicineHumansGeneral Environmental Sciencebusiness.industryFatty liverGeneral Engineeringnutritional and metabolic diseasesArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary Sciences030211 gastroenterology & hepatologySteatohepatitisSteatosisbusinessLiver cancerClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct